Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arbutus Biopharma Corporation - Common Stock (NQ:ABUS)

4.620 -0.030 (-0.65%)
Official Closing Price Updated: 4:15 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arbutus Biopharma Corporation - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Arbutus Announces 2023 Corporate Objectives and Provides Financial Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Completes Enrollment in its Phase 2a Clinical Trial Combining AB-729 with NA Therapy and Peginterferon alfa-2a in Patients with Chronic Hepatitis B Virus Infection
From Arbutus Biopharma Corporation
Via GlobeNewswire
Arbutus Biopharma's Return On Capital Employed Insights ↗
 
Via Benzinga
News headline image
Pfizer, BioNTech Fire Back At Moderna Over COVID-19 Vaccine Related Patent Claims ↗
 
Via Benzinga
News headline image
Arbutus Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Recap: Arbutus Biopharma Q2 Earnings ↗
  Arbutus Biopharma (NASDAQ:ABUS) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Arbutus Biopharma: Q1 Earnings Insights ↗
Arbutus Biopharma (NASDAQ:ABUS) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Arbutus to Present at Jefferies London Healthcare Conference
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Presents AB-729 Clinical Data and AB-101 Preclinical Data at AASLD - The Liver Meeting®
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus Announces Three Poster Presentations with Clinical Data from AB-729 and Preclinical Data from AB-101 at AASLD - The Liver Meeting® 2022
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Arbutus to Report Third Quarter 2022 Financial Results and Provide Corporate Update
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Gaston Picchio, PhD, Chief Development Officer, to Depart Arbutus at Year End
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
Investors can start off the day with a breakdown of the biggest pre-market stock movers for Tuesday and the news moving those shares! 
Via InvestorPlace
News headline image
Moderna Entangles Pfizer/BioNTech In COVID-19 Vaccine Patent Lawsuits: All You Need To Know ↗
Moderna Inc (NASDAQ: MRNA) has  
Via Benzinga
News headline image
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Daily Biotech Pulse: Liver Disease-Focused Gene Therapy Pact, Assembly Bio Stops HBV Infection Trial, X4 Pharma Looks For Partners ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Pfizer Dives As CureVac Tees Up A Patent Suit Aimed At Its BioNTech-Partnered Covid Shot ↗
The company isn't seeking an injunction, but wants "fair compensation." 
Via Investor's Business Daily
News headline image
Pfizer Dives As CureVac Tees Up A Patent Suit Aimed At Its BioNTech-Partnered Covid Shot ↗
The company isn't seeking an injunction, but wants "fair compensation." 
Via Investor's Business Daily
News headline image
This Analyst Says Arbutus' EASL Presentations Outline Path For A Functional Cure For Chronic Hepatitis B ↗
 
Via Benzinga
News headline image
Morning Brief: Top Financial Stories Dominating on Monday, May 9 ↗
CNBC Ford Motor Selling 8M Shares Of Rivian Automotive 
Via Benzinga
News headline image
Moderna Files Motion To Dismiss COVID-19 Vaccine Related Patent Claims: WSJ ↗
Moderna Inc (NASDAQ: MRNA) is trying to fight off rival companies’ patent infringement claims related to its COVID-19 vaccine, arguing that the companies may only pursue their claims by seeking... 
Via Benzinga
News headline image
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Arbutus Biopharma Earnings Conference Call Is Coming Up, Here's What You Need To Know ↗
Arbutus Biopharma (NASDAQ:ABUS) will host a conference call at 08:45 AM ET on May 5, 2022, to discuss Q1 2022 earnings results. 
Via Benzinga
News headline image
Maker Of Pfizer's COVID-19 Vaccine mRNA-Delivery Tech Sues Arbutus Biopharma: Reuters ↗
Canada-based Acuitas Therapeutics Inc has sued Arbutus Biopharma Corporation (NASDAQ: ABUS) in Manhattan federal court, seeking to head off claims that the vaccine infringes Arbutus' patents,  
Via Benzinga
News headline image
Arbutus Biopharma Earnings Perspective: Return On Capital Employed ↗
Benzinga Pro data, Arbutus Biopharma (NASDAQ:ABUS) reported Q4 sales of $3.21 million. Earnings fell to a loss of $21.32 million, resulting in a 11.29% decrease from last quarter... 
Via Benzinga
News headline image
Arbutus Biopharma: Q4 Earnings Insights ↗
Arbutus Biopharma (NASDAQ:ABUS) reported its Q4 earnings results on Thursday, March 3, 2022 at 07:30 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
News headline image
Arbutus Hits Moderna With New Suit Claiming COVID-19 Vaccine Patent(s) ↗
Arbutus Biopharma Corporation (NASDAQ: ABUS) and Genevant have sued Moderna Inc (NASDAQ: MRNA) for infringing on their patent on a lipid... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 2, 2022 ↗
Upgrades Oppenheimer upgraded the previous rating for NovoCure Ltd (NASDAQ:NVCR) from Perform to Outperform. NovoCure earned $0.13 in the third quarter, compared to $0.09... 
Via Benzinga
News headline image
Earnings Scheduled For March 3, 2022 ↗
Companies Reporting Before The Bell • Travelzoo (NASDAQ:TZOO) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban... 
Via Benzinga
News headline image
Futures, Global Markets Soar In Biggest 4-Day Rally Since November 2020 ↗
US equity futures and global stocks from Europe to Asia were headed for the biggest four-day rally since November 2020, supercharged by blockbuster earnings AMD and Google, which hit an all time high... 
Via Talk Markets
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.